SVB Securities lowered the firm’s price target on 4D Molecular to $13 from $14 and keeps a Market Perform rating on the shares. The price target adjustment comes ahead of the Q1 earnings report, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on FDMT:
- 4D Molecular reports FY22 net loss $107.5M vs. $71.3M last year
- 4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights
- Wedbush upgrades Sangamo to Outperform, raises price target to $16
- 4D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials & Development Plans for Fabry Disease Cardiomyopathy at WORLDSymposium™
- 4D Molecular to hold a conference call
